About Mitochondrial carnitine/acylcarnitine carrier protein
Mitochondrial carnitine/acylcarnitine carrier protein (SLC25A20) is a protein
from Homo sapiens identified by UniProt accession
O43772, 301 residues long.
MolForge cross-references it against 0 known binders and
126 disease associations.
Target properties
| Protein name | Mitochondrial carnitine/acylcarnitine carrier protein |
|---|
| UniProt accession | O43772 |
|---|
| Gene | SLC25A20 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 301 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (126)
Diseases linked to this target (Open Targets).
- carnitine-acylcarnitine translocase deficiency · score 0.83
- genetic disorder · score 0.19
- heel bone mineral density · score 0.09
- hepatocellular carcinoma · score 0.08
- neoplasm · score 0.08
- alcohol consumption measurement · score 0.07
- eosinophil count · score 0.07
- atrial fibrillation · score 0.07
- self reported educational attainment · score 0.07
- diastolic blood pressure · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O43772-F1 | alphafold | PREDICTED | 88.84 | — |
Amino-acid sequence (301 residues)
MADQPKPISP LKNLLAGGFG GVCLVFVGHP LDTVKVRLQT QPPSLPGQPP MYSGTFDCFR KTLFREGITG LYRGMAAPII GVTPMFAVCF FGFGLGKKLQ QKHPEDVLSY PQLFAAGMLS GVFTTGIMTP GERIKCLLQI QASSGESKYT GTLDCAKKLY QEFGIRGIYK GTVLTLMRDV PASGMYFMTY EWLKNIFTPE GKRVSELSAP RILVAGGIAG IFNWAVAIPP DVLKSRFQTA PPGKYPNGFR DVLRELIRDE GVTSLYKGFN AVMIRAFPAN AACFLGFEVA MKFLNWATPN L
Explore Mitochondrial carnitine/acylcarnitine carrier protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets